Market Overview

Masimo Signs Far-Reaching Pulse Oximetry Distribution Deal with Butler Schein Animal Health

Masimo (NASDAQ: MASI) announced today that Butler Schein Animal Health, the U.S. animal health business of Henry Schein, Inc. (NASDAQ: HSIC), is now a distributor of Masimo's breakthrough line of pulse oximetry technologies.

Surgical anesthesia used on animals can severely limit peripheral perfusion or blood circulation to the extremities, sometimes making it nearly impossible to get accurate oxygenation and pulse rate readings without the proper technology. Inaccurate readings can delay proper diagnosis and treatment, potentially putting the animal patient's life at risk. Post-surgery, animal patients also need to be monitored for respiratory and cardiovascular problems – a major cause of post-operative death among dogs and cats.1

Masimo's upgradable rainbow® Radical-7® Pulse CO-Oximeter, Rad-87®, Rad-57®, Rad-5® and Rad-8® – all with SET® Measure-Through Motion and Low Perfusion pulse oximetry – will be available to Butler Schein's U.S. client base of more than 26,000 veterinary professionals in all 50 states.

Masimo's technology is designed to provide clinicians oxygen saturation (SpO2) measurements under the most challenging conditions – patient motion and low perfusion, which are common in animal healthcare. Masimo SET® virtually eliminates false alarms2 and increases a clinician's ability to detect life-threatening events.3

"Masimo SET® technology has shown that pulse oximetry can be used reliably in field procedures as well as in the hospital setting," said Lin Klein, VMD, DACVA, who specializes in providing anesthesia services for tigers, leopards, cheetahs, and lions in zoos. "SET® has all but eliminated perfusion-related issues as a source of worry and frustration due to failed or inaccurate SpO2 readings."

"We are thrilled that Butler Schein Animal Health has added Masimo pulse oximetry technology to its impressive line-up of products," said Jon Coleman, President of Worldwide Sales and Marketing and Clinical Research. "Animal healthcare is an important and growing field, and offers Masimo yet another opportunity to take our noninvasive monitoring to new sites and applications."

1 Brodbelt D, Blissitt K, Hammond R, Neath P, Young L, Pfeiffer D, Wood J. "The risk of death: the Confidential Enquiry into Perioperative Small Animal Fatalities." Veterinary Anaesthesia and Analgesia, 2008, 35, 365–373 2 Shah N, Ragaswamy H, Govindugari K, Estanol L. "Performance of three new-generation pulse oximeters during motion and low perfusion in volunteers." Journal of Clinical Anesthesia. 2012 (10.1016/j.jclinane.2011.10.012) Available online here 2 Taenzer, Andreas H.; Pyke, Joshua B.; McGrath, Susan P.; Blike, George T. "Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-and-After Concurrence Study." Anesthesiology, February 2010, Vol. 112, Issue 2. Available online here

About Butler Schein Animal Health Butler Schein Animal Health (Butler Schein) – the U.S. animal health business of Henry Schein, Inc. is the leading companion animal health distribution company in the United States headquartered in Dublin, Ohio. Butler Schein employs approximately 900 team members including 300 field sales representatives and 200 telesales and customer support representatives. With 15 strategically positioned, state-of-the-art distribution facilities and 10 inside sales centers nationwide, we maintain 99%+ order-fill ratio, accomplishing our mission of providing the right product at the right place and at the right time. http://www.butlerschein.com/Site/home/about-us

About Masimo Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to help clinicians detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures; total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), PVI®, and perfusion index (PI), in addition to measure-through motion SpO2, and pulse rate. In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow® Acoustic Monitoring™, the first-ever commercially available noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Masimo SET® and Masimo rainbow® technologies also can be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care ... by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.

Forward-Looking Statements This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results, risks related to our belief that Masimo SET delivers more reliable measurements, virtually eliminates false alarms, and increases a clinician's ability to detect life-threatening events, can be used reliably in field procedures as well as in the hospital setting on animals, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Posted-In: News Contracts

 

Most Popular

Related Articles (HSIC + MASI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free